Abstract Details
|
Anna Roy
PRESENTER |
No disclosure on file |
| Philip Van Damme | The institution of Dr. Van Damme has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for QurAlis. The institution of Dr. Van Damme has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. The institution of Dr. Van Damme has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for VectorY. The institution of Dr. Van Damme has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NRG Therapeutics. The institution of Dr. Van Damme has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Van Damme has received research support from CSL Behring. |
| Martin Freed | No disclosure on file |
| Peter Y. Van Den Bergh, MD, PhD, FAAN (Cliniques Universitaires St Luc, Service de Neurologie) | Dr. Van den Bergh has nothing to disclose. |
| No disclosure on file |